Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 1.00 |
| ▸ | ITGA2B | P08514 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Roxifiban SCHEMBL24336949 | 0.94 | ITGB3 (1.00) | ITGB3ITGA2B | |
| Roxifiban SCHEMBL344302 | 0.94 | ITGB3 (1.00) | ITGB3ITGA2B | |
| Roxifiban SCHEMBL919675 | 0.93 | ITGB3 (0.95) | ITGB3ITGA2B | |
| SCHEMBL7219528 | 0.91 | ITGB3 (0.83) | ITGB3ITGA2B | |
| SCHEMBL7219511 | 0.91 | ITGB3 (0.83) | ITGB3ITGA2B | |
| Roxifiban SCHEMBL50632 | 0.87 | ITGB3 (0.86) | ITGB3ITGA2B | |
| SCHEMBL6128667 | 0.86 | ITGB3 (0.76) | ITGB3ITGA2B | |
| SCHEMBL7213402 | 0.86 | ITGB3 (0.77) | ITGB3ITGA2B | |
| SCHEMBL7220986 | 0.84 | ITGB3 (0.83) | ITGB3ITGA2B | |
| SCHEMBL7407564 | 0.82 | ITGB3 (0.80) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6623981-B2 | Detecting antibodies which bind integrin bound modulators; obtain sample, incubate with modulators and antibodies, form complexes, screen for bound complex | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-23 | — | — | US | claimed |
| US-20020132276-A1 | FACS method for detecton of GPIIb/IIIa inhibitor dependent activators in plasma samples | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-19 | — | — | US | claimed |
| US-20020081632-A1 | Assays to assess conformational changes of integrins induced by ligand binding based on electrophoretic mobility | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-27 | — | — | US | claimed |
| US-20020081624-A1 | DETECTION OF PATIENTS AT RISK FOR DEVELOPING INTEGRIN ANTAGONIST/ AGONIST MEDIATED DISEASE STATES | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-27 | — | — | US | claimed |
| EP-3157408-B1 | DEVICES TO PROVIDE HANDS FREE SCLERAL DEPRESSION DURING OPHTHALMIC PROCEDURES | ALCON INC (CH) | 2026-03-25 | — | — | EP | disclosed |
| EP-4714407-A2 | DEVICES TO PROVIDE HANDS FREE SCLERAL DEPRESSION DURING OPHTHALMIC PROCEDURES | Alcon Inc. (CH) | 2026-03-25 | — | — | EP | disclosed |
| CN-114652816-B | Compositions containing HC-HA/PTX3 complexes and methods of use thereof | 生物组织控股公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20250057694-A1 | DEVICES AND METHODS TO PROVIDE HANDS FREE SCLERAL DEPRESSION AND ILLUMINATION DURING OPHTHALMIC PROCEDURES | Ganihand, LLC (US) | 2025-02-20 | — | — | US | disclosed |
| US-20230279048-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2023-09-07 | — | — | US | disclosed |
| US-11518782-B2 | Compositions containing HC-HA/PTX3 complexes and methods of use thereof | TISSUETECH, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| CN-114652816-A | Compositions containing HC-HA/PTX3 complexes and methods of use thereof | 组织技术公司 | 2022-06-24 | — | — | CN | disclosed |
| US-11266395-B2 | Devices and methods to provide hands free scleral depression during ophthalmic procedures | Ganihand, LLC (US) | 2022-03-08 | — | — | US | disclosed |
| CN-104619352-B | Compositions containing HC-HA/PTX3 complexes and methods of use thereof | 组织技术公司 | 2022-02-18 | — | — | CN | disclosed |
| US-6623981-B2 | Detecting antibodies which bind integrin bound modulators; obtain sample, incubate with modulators and antibodies, form complexes, screen for bound complex | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-20020132276-A1 | FACS method for detecton of GPIIb/IIIa inhibitor dependent activators in plasma samples | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-19 | — | — | US | disclosed |
| US-20020081632-A1 | Assays to assess conformational changes of integrins induced by ligand binding based on electrophoretic mobility | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-27 | — | — | US | disclosed |
| US-20020081624-A1 | DETECTION OF PATIENTS AT RISK FOR DEVELOPING INTEGRIN ANTAGONIST/ AGONIST MEDIATED DISEASE STATES | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-27 | — | — | US | disclosed |